Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

NCT00715637 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Interventions

DRUG: Daunorubicin and Cytarabine
DRUG: Amonafide and Cytarabine

Sponsor

Antisoma Research